Table 1 Expression of GSK3α/GSK3β in various OSCC and control samples - their correlation with clinico-pathological parameters
Sl. No. | Groups | Total (N = 80) | GSK3α | GSK3β | p-value (GSK3β over GSK3α ) | |||
|---|---|---|---|---|---|---|---|---|
Expression | Overexpression | Expression | Overexpression | Expression | Overexpression | |||
1 | Age | |||||||
≤40 | 15 | 08 (53.3%) | 00 (00.0%) | 09 (60.0%) | 03 (20.0%) | NS | 0.06 | |
>40 ≤ 70 | 53 | 25 (47.1%) | 05 (09.4%) | 36 (67.9%) | 20 (37.7%) | 0.03 | 0.0006 | |
>70 | 12 | 06 (50.0%) | 00 (00.0%) | 09 (75.0%) | 07 (58.3%) | NS | 0.001 | |
2 | Sex | |||||||
Male | 49 | 26 (53.0%) | 04 (08.1%) | 33 (67.3%) | 19 (38.7%) | NS | <0.0001 | |
Female | 31 | 13 (41.9%) | 01 (03.2%) | 20 (64.5%) | 10 (32.2%) | NS | 0.002 | |
3 | Size | |||||||
T1-T2 | 40 | 18 (45.0%) | 03 (07.5%) | 30 (75.0%) | 23 (57.5%) | 0.006 | <0.0001 | |
T3-T4 | 2 | 02 (100%) | 00 (00.0%) | 02 (100%) | 01 (50.0%) | NS | NS | |
4 | Lymph nodes | |||||||
N0 | 42 | 19 (45.2%) | 03 (07.1%) | 28 (66.6%) | 20 (47.6%) | 0.04 | <0.0001 | |
N1-N3 | 4 | 02 (50.0%) | 01 (25.0%) | 03 (75.0%) | 03 (75.0%) | NS | NS | |
5 | Distant Metastasis | |||||||
M0 | 38 | 19 (50.0%) | 03 (07.8%) | 28 (73.6%) | 19 (50.0%) | 0.03 | <0.0001 | |
M1 | 8 | 03 (37.5%) | 01 (12.5%) | 07 (87.5%) | 07 (87.5%) | 0.03 | 0.002 | |
6 | Histological grade | |||||||
WDSCC | 24 | 17 (70.8%) | 02 (08.3%) | 21 (87.5%) | 18 (75.0%) | NS | <0.0001 | |
MDSCC | 7 | 03 (42.8%) | 01 (14.2%) | 07(100%) | 05 (71.4%) | NS | NS | |
PDSCC | 7 | 02 (28.5%) | 01 (14.2%) | 04 (57.1%) | 03 (42.8%) | NS | NS | |
7 | Oral cancer types | |||||||
SCC | 32 | 18 (56.2%) | 03 (09.3%) | 27 (84.3%) | 24 (75.0%) | 0.02 | <0.0001 | |
Invasive SCC | 5 | 02 (40.0%) | 01 (20.0%) | 03 (60.0%) | 03 (60.0%) | NS | NS | |
Mucoepidermoid carcinoma | 8 | 04(50.0%) | 01 (12.5%) | 06 (75.0%) | 03 (37.5%) | NS | NS | |
Adamantinoma | 8 | 03 (37.5%) | 0 (00.0%) | 05 (62.5%) | 01 (12.5%) | NS | NS | |
Adenoid cystic carcinoma | 3 | 00 (00.0%) | 00 (00.0%) | 00 (00.0%) | 00 (00.0%) | N/A | N/A | |
Basal cell carcinoma | 2 | 00 (00.0%) | 00 (00.0%) | 01 (50.0%) | 00 (00.0%) | N/A | N/A | |
Acinic cell carcinoma | 1 | 00 (00.0%) | 00 (00.0%) | 01 (50.0%) | 00 (00.0%) | N/A | N/A | |
9 | Hyperplasia of Squamous Epithelium | 6 | 03 (50.0%) | 01 (16.6%) | 04 (66.6%) | 01 (16.6%) | NS | NS |
10 | Cancer adjacent oral tissue | 5 | 01 (20.0%) | 00 (00.0%) | 03 (60.0%) | 00 (00.0%) | NS | NS |
11 | Non neoplastic oral cavity glands | 11 | 07 (63.6%) | 00 (00.0%) | 06 (54.5%) | 00 (00.0%) | NS | NS |
12 | Normal oral squamous epithelium | 4 | 03 (75.0%) | 00 (00.0%) | 01 (25.0%) | 01 (25.0%) | NS | NS |
13 | Sub-types of OSCC | |||||||
Tongue | 10 | 08 (80.0%) | 01 (10.0%) | 08 (80.0%) | 07 (70.0%) | NS | 0.006 | |
Lip | 7 | 03 (42.8%) | 00 (00.0%) | 07 (100%) | 07 (100%) | 0.01 | 0.0002 | |
Cheek | 6 | 03 (50.0%) | 00 (00.0%) | 05 (83.3%) | 03 (50.0%) | NS | 0.04 | |
Gingiva | 4 | 02 (50.0%) | 00 (00.0%) | 04 (100%) | 04 (100%) | NS | 0.004 | |
Others | 5 | 02 (40.0%) | 03 (60.0%) | 03 (60.0%) | 03 (60.0%) | NS | NS | |